Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fenghai Duan

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
Tomography (Ann Arbor, Mich.)|April 30, 2021
Whole-Body [<sup>18</sup>F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687Mark Muzi, Finbarr O'Sullivan, Timothy G Perk, et al.
The Journal of Urology|September 5, 2018
The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE TrialGerald L Andriole, Lale Kostakoglu, Albert Chau, et al.
Genes, Chromosomes & Cancer|March 27, 2012
Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology GroupFenghai Duan, Lynette M Smith, Donna M Gustafson, et al.
Cancer|July 29, 2014
Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening TrialIlana F Gareen, Fenghai Duan, Erin M Greco, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2012
Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohortsBruce E Hillner, Barry A Siegel, Lucy Hanna, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2017
Hospice Admission and Survival After <sup>18</sup>F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET RegistryIlana F Gareen, Bruce E Hillner, Lucy Hanna, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2016
Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235Jose G Bazan, Fenghai Duan, Bradley S Snyder, et al.
Plos One|October 3, 2018
Correction: Novel high-resolution computed tomography-based radiomic classifier for screen-identified pulmonary nodules in the National Lung Screening TrialTobias Peikert, Fenghai Duan, Srinivasan Rajagopalan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
PET and PET/CT reports: observations from the National Oncologic PET RegistryR Edward Coleman, Bruce E Hillner, Anthony F Shields, et al.
Cancer|January 3, 2013
Examining whether lung screening changes risk perceptions: National Lung Screening Trial participants at 1-year follow-upElyse R Park, Ilana F Gareen, Amanda Jain, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Tomography (Ann Arbor, Mich.)|April 30, 2021
Whole-Body [<sup>18</sup>F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687Mark Muzi, Finbarr O'Sullivan, Timothy G Perk, et al.
The Journal of Urology|September 5, 2018
The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE TrialGerald L Andriole, Lale Kostakoglu, Albert Chau, et al.
Genes, Chromosomes & Cancer|March 27, 2012
Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology GroupFenghai Duan, Lynette M Smith, Donna M Gustafson, et al.
Cancer|July 29, 2014
Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening TrialIlana F Gareen, Fenghai Duan, Erin M Greco, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2012
Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohortsBruce E Hillner, Barry A Siegel, Lucy Hanna, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2017
Hospice Admission and Survival After <sup>18</sup>F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET RegistryIlana F Gareen, Bruce E Hillner, Lucy Hanna, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2016
Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235Jose G Bazan, Fenghai Duan, Bradley S Snyder, et al.
Plos One|October 3, 2018
Correction: Novel high-resolution computed tomography-based radiomic classifier for screen-identified pulmonary nodules in the National Lung Screening TrialTobias Peikert, Fenghai Duan, Srinivasan Rajagopalan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 17, 2009
PET and PET/CT reports: observations from the National Oncologic PET RegistryR Edward Coleman, Bruce E Hillner, Anthony F Shields, et al.
Cancer|January 3, 2013
Examining whether lung screening changes risk perceptions: National Lung Screening Trial participants at 1-year follow-upElyse R Park, Ilana F Gareen, Amanda Jain, et al.
Pageof 8